Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00261365 · ClinicalTrials.gov registry record · Phase 1
Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
NCT00261365 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 80 participants.
The verdict
NCT00261365, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
Study Summary
The purpose of this study is to identify candidate markers predictive of response and/or serious toxicity to BMS-734016 (MDX-010).
Interventions
- DRUG Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2005-11 |
| Est. Completion | 2007-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00261365
The ClinicalTrials.gov registry entry for NCT00261365 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ipilimumab is the first listed.
NCT00261365 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00261365 about?
NCT00261365 is a clinical study titled "Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)". The purpose of this study is to identify candidate markers predictive of response and/or serious toxicity to BMS-734016 (MDX-010).
What is the current status of trial NCT00261365?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2005-11. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00261365?
The interventions under investigation include: Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT00261365?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.